Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Stock Summary
- Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than just 4.25% of US equities in our set.
- With a price/sales ratio of 47.18, Xeris Pharmaceuticals Inc has a higher such ratio than 96.26% of stocks in our set.
- In terms of volatility of its share price, XERS is more volatile than 94.25% of stocks we're observing.
- Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are SWAV, ASTC, NWBO, RIGL, and AKER.
- XERS's SEC filings can be seen here. And to visit Xeris Pharmaceuticals Inc's official web site, go to www.xerispharma.com.
XERS Stock Price Chart More Charts
XERS Price/Volume Stats
|Current price||$5.14||52-week high||$12.94|
|Prev. close||$5.35||52-week low||$1.42|
|Day high||$5.28||Avg. volume||623,587|
|50-day MA||$2.72||Dividend yield||N/A|
|200-day MA||$6.34||Market Cap||193.20M|
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.